Understanding The DOL Final PBM Fee Disclosure Rule
Plan sponsors must now systematically collect and verify pharmacy benefit manager fee data to ensure full compliance with the Department of Labor’s new disclosure requirements. This process involves requesting detailed information from PBMs regarding all fees, including those paid to pharmacies, wholesalers, and specialty pharmacies. Sponsors should establish clear timelines for receiving these disclosures and implement internal review protocols to validate the accuracy and completeness of the submitted data. It is essential to understand that the rule mandates transparency in fee structures that directly impact plan costs and participant benefits. By proactively engaging with service providers, sponsors can identify potential discrepancies and negotiate more favorable terms. This diligent approach not only satisfies regulatory obligations but also strengthens fiduciary oversight by providing a clearer picture of plan expenses. Sponsors should document all interactions and requests to maintain a robust compliance record.
Also worth reading: How Can AI Healthcare Audit Best Practices Enhance Compliance and Efficiency? · How Does AI PBM Fiduciary Audit Ensure Compliance with ERISA Standards? · How does health plan AI compliance ensure regulatory adherence in modern healthcare?
Effective navigation of these best practices requires ongoing monitoring and adaptation as regulatory guidance evolves. Sponsors should integrate PBM fee disclosures into their annual ERISA Form 5500 filing processes, ensuring that all required information is accurately reported. Regular audits and third-party reviews can help identify areas where fee transparency might be lacking. Furthermore, plan sponsors should educate their administrative teams about the significance of these disclosures and the potential liabilities associated with non-compliance. By fostering a culture of transparency and accountability, sponsors can better protect plan assets and enhance participant trust. It is crucial to stay informed about any future updates or clarifications issued by the DOL regarding PBM fee disclosures. This proactive stance ensures that plan sponsors remain ahead of regulatory changes and maintain robust compliance standards throughout the year.
Implementing Transparent PBM Compensation Models
With the Department of Labor's final ERISA PBM fee disclosure rule, plan sponsors can no longer accept vague summaries of how their pharmacy benefit managers are compensated. As fiduciaries, they are now expected to obtain detailed breakdowns of both direct and indirect fees, including spread pricing, manufacturer rebates, and administrative charges. This level of scrutiny is critical, as many PBM contracts have historically concealed revenue streams that could directly conflict with a plan's duty of loyalty. Simply collecting these reports, however, is not enough. Sponsors must be able to interpret them and demonstrate that the total compensation received is reasonable for the services provided.
To meet evolving compliance expectations, ERISA plan sponsors should document their entire review process and compare new disclosures against prior contracts for inconsistencies. Many are also renegotiating agreements to secure ongoing transparency rather than one-time reports. While this rule marks a major step forward, broader PBM reform remains stalled in Congress, leaving some gaps in accountability. By shifting from passive oversight to active monitoring, sponsors can strengthen their fiduciary defense, reduce litigation risk, and ultimately work toward more sustainable prescription drug costs for their participants.
Auditing Pharmacy Benefit Manager Conflicts Of Interest
ERISA plan sponsors should treat new PBM disclosure expectations as an operating discipline, not a one-time paperwork exercise. Start by mapping every PBM compensation stream, rebate arrangement, spread pricing term, and affiliate relationship against the plan document and service agreement. Then request standardized reporting, verify data definitions, and compare disclosed amounts to invoices, claims files, and reconciliation reports. Sponsors should document fiduciary review, assign owners for follow-up, and escalate discrepancies before renewal or amendment. Because DOL activity and market practice continue to evolve, sponsors should keep a dated compliance file, monitor guidance, and train internal teams on disclosure duties.
A practical approach is to build a repeatable audit calendar around quarterly PBM reporting, annual fiduciary review, and pre-renewal benchmarking. Sponsors can use independent consultants, legal counsel, and pharmacy analytics to test whether disclosures are complete, timely, and understandable. They should require correction of errors, preserve evidence of diligence, and negotiate contract language supporting ongoing transparency. The goal is not merely to receive disclosures, but to understand them well enough to protect participants, control costs, and demonstrate prudent fiduciary process.
Ensuring Fiduciary Compliance With New Disclosure Rules
For ERISA plan sponsors, meeting the newly finalized PBM fee disclosure requirements starts with a shift in mindset. Rather than viewing pharmacy costs as a fixed line item, fiduciaries must now treat compensation details as material to their duty of prudence. This means reviewing current PBM contracts line by line to identify any gaps in reporting and confirming whether those agreements obligate the PBM to provide the full scope of direct and indirect fees. Waiting until a deadline nears leaves little room to address missing information, so early engagement is often the most effective first step toward compliance.
As disclosures begin to come in, plan sponsors cannot simply accept them at face value. Each response should be evaluated for completeness, and any vague or bundled fees should be followed up on in writing to create a clear audit trail. Documenting these efforts is just as critical as obtaining the data itself, as it demonstrates a prudent process to the Department of Labor if reviewed. Ultimately, these best practices do more than satisfy a new rule, they reinforce the core ERISA obligation to act solely in the interest of plan participants and beneficiaries.
Leveraging AI For Streamlined PBM Transparency Reporting
ERISA plan sponsors now face finalized Department of Labor rules requiring detailed disclosure of pharmacy benefit manager compensation, and navigating these requirements demands a structured approach. The first step is reviewing existing PBM service agreements to identify which arrangements fall within the scope of the new disclosure obligations, including fees tied to formulary placement, rebates, and spread pricing. Sponsors should then formally request the required disclosures in writing, documenting all communications to establish a good-faith compliance record. Because PBMs may be slow or incomplete in their responses, plan fiduciaries should compare submitted data against contract terms and benchmark data to spot discrepancies that could signal overcharges or conflicts of interest.
For many sponsors, the volume and complexity of PBM fee data make manual review impractical, which is where AI-driven tools add value. Intelligent platforms can parse disclosure documents, flag unusual compensation structures, and benchmark costs across comparable plans far faster than traditional audits. Healtho.io helps plan sponsors translate these new transparency requirements into actionable oversight, turning compliance paperwork into genuine cost savings and stronger fiduciary protection.
PBM Disclosure Compliance Checklist
| Compliance Step | Sponsor Action | Compliance Value |
|---|---|---|
| Map ERISA plan data flows | Inventory PBMs, contracts, fee arrangements, and data sources | Establishes a fiduciary record and reveals disclosure gaps |
| Review PBM contract terms | Align confidentiality, audit, pass-through, and reporting clauses with DOL final rule requirements | Prevents contractual barriers to required fee disclosure |
| Collect and validate fee disclosures | Request itemized PBM fees, compensation, and conflicts; reconcile against claims data | Supports accurate plan cost analysis and prudent decisions |
| Document and monitor | Retain disclosure records, compare vendor responses, and schedule annual reviews | Demonstrates ongoing ERISA fiduciary oversight |